Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

This study has been completed.
National Cancer Institute (NCI)
Norris Cotton Cancer Center
Information provided by:
Dartmouth-Hitchcock Medical Center Identifier:
First received: April 7, 2004
Last updated: August 4, 2009
Last verified: August 2009

April 7, 2004
August 4, 2009
January 2004
April 2005   (final data collection date for primary outcome measure)
Clinical benefit rate (complete response, partial response, and stable disease) for 26 weeks [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00080743 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
ZD1839 (IRESSA) In Tamoxifen-Resistant Metastatic Breast Cancer

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. Combining gefitinib with tamoxifen may be effective in killing tumor cells that have become resistant (stopped responding) to tamoxifen.

PURPOSE: This randomized phase II trial is studying how well giving gefitinib together with tamoxifen works compared to gefitinib alone in treating patients with metastatic breast cancer that has stopped responding to tamoxifen.



  • Compare the rate of clinical benefit in patients with tamoxifen-resistant breast cancer treated with gefitinib with or without tamoxifen.


  • Determine the toxic effects of these regimens in these patients.
  • Determine whether changes in fludeoxyglucose F 18 uptake by positron emission tomography scan and changes in plasma DNA levels are indicators of an early response to gefitinib in these patients.
  • Determine the pharmacokinetics of these regimens in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to population (intent-to-treat population comprising all patients who receive 1 dose of treatment vs a subset of the intent-to-treat population, excluding patients with nonmeasurable/evaluable only disease). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral tamoxifen once daily. Beginning 14 days after the start of tamoxifen, patients receive oral gefitinib once daily.
  • Arm II: Patients receive oral placebo once daily. Beginning 14 days after the start of placebo, patients receive oral gefitinib as in arm I.

In both arms, treatment continues for 26 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed for 6 months.

PROJECTED ACCRUAL: A total of 46 patients (23 per treatment arm) will be accrued for this study within 23 months.

Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Breast Cancer
  • Drug: gefitinib
    250 mg po once daily
    Other Name: ZD1839, Iressa
  • Drug: tamoxifen citrate
    20 mg po once daily
    Other Name: Nolvadex
  • Drug: Placebo
    One pill po once daily
    Other Name: Sugar pill
  • Active Comparator: Tamoxifen
    Tamoxifen 20 mg po once daily
    • Drug: gefitinib
    • Drug: tamoxifen citrate
  • Placebo Comparator: Placebo
    Placebo comparator one tablet po once daily
    • Drug: gefitinib
    • Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2005
April 2005   (final data collection date for primary outcome measure)


  • Histologically confirmed breast cancer

    • Metastatic disease
  • Initial clinical benefit from tamoxifen for metastatic disease, defined by 1 of the following:

    • Stable disease for 24 weeks or longer
    • Objective tumor response
  • Documentation of clinical progression on tamoxifen within the past 6 weeks
  • Hormone receptor status:

    • Estrogen or progesterone receptor positive on most recently analyzed biopsy



  • 18 and over


  • Not specified

Menopausal status

  • Not specified

Performance status

  • ECOG 0-2

Life expectancy

  • At least 6 months


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3


  • AST ≤ 1.5 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN


  • Creatinine ≤ 1.5 times ULN OR
  • Creatinine clearance ≥ 50 mL/min


  • No clinically active interstitial lung disease

    • Patients with asymptomatic chronic stable radiographic changes are eligible


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No known hypersensitivity to gefitinib
  • No other malignancy within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix


Biologic therapy

  • No concurrent trastuzumab (Herceptin®)


  • No concurrent cytotoxic chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • At least 2 weeks since other prior tamoxifen
  • No concurrent hormone replacement therapy
  • No other concurrent antiestrogens, including raloxifene
  • No concurrent aromatase inhibitors
  • No concurrent megestrol
  • Concurrent systemic steroids for reasons other than skin toxicity allowed provided the steroids were initiated before study entry AND dose remains stable


  • Concurrent palliative radiotherapy as short-term treatment for symptomatic bone metastases allowed provided other evaluable sites of disease are present AND treatment lasts no more than 14 days


  • Recovered from prior oncologic or other major surgery
  • No concurrent surgery during and for 7 days after study treatment
  • No concurrent ophthalmic surgery


  • Recovered from all prior therapy (except alopecia)
  • More than 30 days since prior investigational drugs
  • No other concurrent investigational agents
  • No concurrent administration of any of the following:

    • Phenytoin
    • Carbamazepine
    • Barbiturates
    • Rifampin
    • Phenobarbital
    • Hypericum perforatum (St. John's wort)
    • Systemic retinoids
    • CYP3A4 inhibitors (e.g., itraconazole)
    • Drugs that cause significant sustained elevation in gastric pH ≥ 5
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
CDR0000355145, DMS-0236, ZENECA-IRUSIRES0162
Gary N. Schwartz, Dartmouth-Hitchcock Medical Center
Dartmouth-Hitchcock Medical Center
  • National Cancer Institute (NCI)
  • Norris Cotton Cancer Center
Principal Investigator: Gary N. Schwartz, MD Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP